ASEAN CSDT Dossier Structure for Indonesian Medical Device Registration

1. Key takeaways

Indonesia files device submissions in the ASEAN Common Submission Dossier Template, and has done so as a matter of course since 2018. In that year Indonesia aligned with the ASEAN Medical Device Directive (AMDD), and technical documentation for imported devices must be organised to the CSDT. This is not an advisory format. It is the established structure against which reviewers read the file, and a dossier that ignores it is read with difficulty before it is read on its merits.

The CSDT is best understood as a reading map for the reviewer rather than a filing checklist. Its core sections are fixed, and each one answers a specific question the reviewer will otherwise have to ask. A file that follows the template lets the reviewer move through it; a file that does not forces the reviewer to reconstruct the argument, and reviewers respond to that by issuing questions instead of conclusions.

• Executive summary: covering the marketing history, the intended use, approvals obtained in other countries, and significant safety or performance information.
• Essential Principles Checklist: the clause-by-clause conformity statement against the Essential Principles of Safety and Performance.
• Declaration of Conformity: the manufacturer’s formal attestation.
• Device description and intended use: what the product is and what it is claimed to do.
• Design verification and validation: the evidence that the design does what the description says.
• Device labelling: the label and instructions for use.
• Risk analysis: prepared under ISO 14971.
• Manufacturer information: who makes the product and under which quality system.

Beyond the core template, the supplementary set depends on the product. It typically includes materials information, the production process, packaging, verification and validation records, performance evidence such as certificates of analysis, stability data, sterilisation records and electrical safety testing, risk management documentation, sterility evidence where applicable, labels and instructions for use, and post-market procedures. For Class C and Class D devices, preclinical or clinical evidence is added on top.

2. Legal basis

The template obligation rests on Indonesia’s alignment with the AMDD, which has governed the imported-device dossier since 2018. The current regulatory layer is set by Permenkes No. 11/2025, Appendix 3, which states the documentation requirements for imported devices, and by Permenkes No. 5/2026, whose provisions on classification and marketing authorisation determine how much evidence a given class must carry. Risk analysis is prepared to ISO 14971. The references below were verified on 26 October 2026.

The language rule deserves a precise reading, because it is frequently misread. The technical dossier may be submitted in English, but user-facing content — labels, instructions for use and packaging — must be in Indonesian (see article 25). Permission to submit in English extends to the technical file only. It never extends to the documents the end user will read.

3. Expert insights

Insight 1: the executive summary is the highest-leverage page in the dossier, and the most commonly underwritten. It is the first thing a reviewer reads, and three recurring failures are traced back to weaknesses that start there. The summary must carry enough of the marketing history, approvals in other countries and safety essentials for the reviewer to orient before diving into the modules. Chinese manufacturers lose marks here most often because the summary is too brief — written as a preamble rather than as the opening argument of the file.

Insight 2: a copied Essential Principles Checklist is worse than a short one. The second classic failure is reproducing the template checklist verbatim, without stating how each principle is met and which piece of evidence supports it. A checklist that answers every clause with a bare conformity claim gives the reviewer nothing to verify against, and it will be sent back. The discipline is to pair every clause with its method of compliance and its evidence pointer.

Insight 3: design verification and validation needs conclusions and summaries. The third failure mode is a design V&V section that presents results without summaries, leaving the reviewer unable to judge the strength of the evidence without reading every report in full. A short synthesis per test — what was tested, to which acceptance criterion, with what outcome — converts a data dump into an argument, and it is the difference between a file that reassures and a file that raises questions.

Insight 4: readability has a measurable cost when neglected. Each section should let the reviewer find the conclusion and the pointer to its evidence within 30 seconds. That standard sounds cosmetic, but the readability of the dossier directly affects the number of deficiency rounds: every question the reviewer must formulate is a round trip, and every round trip is months.

4. Practical recommendations

• Write the executive summary as an argument, not a preamble. Cover the marketing history, approvals in other countries and the significant safety points with enough substance for a reviewer to orient in one reading.
• Fill the Essential Principles Checklist with method and evidence, not bare claims. For each principle, state how it is satisfied and name the report or section that proves it.
• Add a summary layer to design verification and validation. Give each test a short synthesis with the acceptance criterion and the outcome before the raw reports.
• Treat the CSDT as a reading map. Structure every section so a reviewer can locate the conclusion and its evidence pointer within 30 seconds.
• Split the language strategy in two. Keep the technical dossier in English, and budget separately for professionally translated Indonesian labels, IFU and packaging.
• Scale the supplementary set to the class. For Class C and D devices, plan the preclinical or clinical evidence workstream alongside the dossier writing, not after it.

The unifying principle behind these recommendations is that a dossier is read before it is judged. Reviewers do not reward volume; they reward files in which each section states its conclusion, points to its evidence and stays consistent with the others. Teams that internalise this tend to see fewer and narrower deficiency rounds, because the reviewer’s questions are answered in advance by the structure of the file itself.

5. Verification checklist

• □ Dossier structured to the ASEAN CSDT, as harmonised with the AMDD since 2018
• □ Import documentation requirements checked against Permenkes No. 11/2025, Appendix 3
• □ Evidence depth confirmed against the classification and marketing authorisation provisions of Permenkes No. 5/2026
• □ Risk analysis prepared under ISO 14971
• □ Executive summary covers marketing history, foreign approvals and significant safety or performance information
• □ Essential Principles Checklist states the method of compliance and the evidence pointer for each principle
• □ Design verification and validation section carries summaries, not only conclusions
• □ Labels, IFU and packaging prepared in Indonesian; technical dossier in English

This article was prepared by GRZAN on the basis of publicly available regulations, with data verified as of 26 October 2026. It is provided for industry exchange and does not constitute legal advice; documentation requirements are governed by what Kemenkes publishes for the time being in force.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Indonesia. Our team prepares dossiers to ASEAN CSDT structure, manages AKL/AKL-I submissions with Kemenkes, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com